Salvage Radiotherapy Confers an Overall Survival Advantage in Biochemical Recurrence of Prostate Cancer: Evidence from the International PROMISE Registry - PubMed
3 hours ago
- #overall survival
- #salvage radiotherapy
- #prostate cancer
- Salvage radiotherapy (SRT) improves overall survival in prostate cancer patients with biochemical recurrence after prostatectomy.
- Analysis of the PROMISE registry (1410 patients, median 5.2-year follow-up) showed SRT associated with longer OS (HR 0.66, p=0.019), with 7-year survival rates of 90.8% vs 83.8% without SRT.
- Subgroup analysis found significant OS benefit for PET-negative (miT0N0M0) disease (HR 0.42, p=0.0061), especially with PSA ≤0.5 ng/mL.
- Study used comprehensive restaging with serologic markers and PSMA-targeted PET imaging (PET/CT or PET/MRI) to assess molecular TNM stage.
- SRT was administered to 56% of PET-negative and 65% of PET-locoregional disease patients after PET imaging.
- Conclusion highlights SRT improves OS, particularly for patients with negative PSMA-targeted PET findings at recurrence.